Key result
High pan-immune inflammation value is linked to ~36% higher all-cause mortality in cancer survivors.
Why the study?
Does a high pan-immune inflammation value predict all-cause, CVD, and cancer-specific mortality in cancer survivors?
Cohort (n=3,773)
Yes
Does a high pan-immune inflammation value predict all-cause, CVD, and cancer-specific mortality in cancer survivors?
Answers are grounded in this paper and cite their sources.
Elevated pan-immune inflammation value independently predicts higher all-cause and cancer-specific mortality in cancer survivors, with renal function partially mediating the effect.
BACKGROUND: This study examines whether the pan-immune inflammation value (PIV) is linked to all-cause, cardiovascular disease (CVD), and cancer-specific mortality in individuals with a history of cancer. Data from the National Health and Nutrition Examination Survey (NHANES) were analyzed to further explore the potential mediating influence of estimated glomerular filtration rate (eGFR) on the PIV-mortality relationship. METHODS: We included 3773 cancer survivors from NHANES (2003-2018). Mortality follow-up was conducted via linkage to the National Death Index. Associations between PIV and mortality outcomes were assessed using restricted cubic spline curves and weighted multivariable Cox regression. Mediation analysis evaluated whether eGFR partly explains the effect of PIV on mortality. RESULTS: Over a median follow-up of 84.75 months, 1137 deaths occurred (all-cause: 30.14 %; CVD: 8.32 %; cancer: 9.09 %). Using an optimal cutoff of 344.63, participants were classified into low (n = 2335) and high PIV (n = 1438) groups. In fully adjusted models, high PIV was associated with increased risks of all-cause mortality (HR 1.36, 95 % CI 1.18-1.56) and cancer-related mortality (HR 1.42, 95 % CI 1.10-1.82). eGFR mediated 9.10 % of the association between PIV and all-cause mortality and 11.47 % for CVD mortality, but not significantly for cancer mortality. CONCLUSION: Elevated PIV independently predicts higher all-cause and cancer-specific mortality in cancer survivors. The findings suggest that PIV may serve as a practical prognostic marker, with renal function partially accounting for its link to mortality.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2025) conducted a cohort in Cancer survivors (n=3,773). High pan-immune inflammation value (PIV ≥ 344.63) vs. Low pan-immune inflammation value (PIV < 344.63) was evaluated on All-cause mortality (HR 1.36, 95% CI 1.18-1.56). High pan-immune inflammation value was associated with increased risks of all-cause mortality and cancer-related mortality in cancer survivors.
Synapse has enriched 10 related papers. Consider them for comparative context: